Jérôme Guicheux

USPTO Granted Patents = 8 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 48(Granted Patents)

Location History:

Nantes, FR (2008 - 2020)
Sainte Luce sur Loire, FR (2020)

Company Filing History:

8 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

The University of Nantes

patent

7. 1 out of 19

Institut Francais De Recherche Pour L'exploitation De La Mer (ifremer)

patents

8. 1 out of 1

Ecole Nationale Veterinaire

patent

9. 1 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2020

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10632203 - Silylated biomolecule-based hydrogel for culturing cardiomyocytes and stem cells, and use of the hydrogel thereof for treating heart failure (2020-04-28),

2. 10632154 - Si-HPMC-encapsulated insulin-producing cells for the treatment of type 1 diabetes (2020-04-28),

3. 9968681 - Silylated biomolecule-based hydrogel for culturing cardiomyocytes and stem cells, and use of the hydrogel thereof for treating heart failure (2018-05-15),

4. 9285360 - Silylated biomolecules (2016-03-15),

5. 8440462 - Use of a hydrogel for the culture of chondrocytes (2013-05-14),

6. 8044037 - Modified phosphocalcic compound, injectable composition containing same (2011-10-25),

7. 7521436 - Modified phosphocalcic compound, injectable composition containing same (2009-04-21),

8. 7351280 - Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment (2008-04-01),

Title: Inventor Jérôme Guicheux: Pioneering Innovations in Diabetes and Cardiology

Introduction

Jérôme Guicheux is a notable inventor based in Nantes, France, recognized for his significant contributions to medical innovations. With a total of six patents to his name, Guicheux is focused on developing advanced treatments for critical health conditions, particularly in diabetes and heart failure.

Latest Patents

Among his latest inventions, Guicheux has developed two groundbreaking patents. The first one, titled "Si-HPMC-encapsulated insulin-producing cells for the treatment of type 1 diabetes," relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC). This innovation aims to restore and maintain euglycemia in type 1 diabetic patients and those in the prediabetic stage.

The second patent, "Silylated biomolecule-based hydrogel for culturing cardiomyocytes and stem cells, and use of the hydrogel for treating heart failure," revolves around a hydrogel that supports the three-dimensional culture of cardiomyocytes or stem cells. It is intended for treating heart failure, particularly post-myocardial infarction, by utilizing a specialized biomolecule composition.

Career Highlights

Guicheux has worked with prestigious institutions, including the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Université de Nantes. His experience in these organizations has provided a solid foundation for his research and innovations in the biomedical field.

Collaborations

Throughout his career, Guicheux has collaborated with notable professionals such as Guy Daculsi and Pierre Weiss. These partnerships have bolstered his research efforts and contributed to the success of his inventive endeavors.

Conclusion

Jérôme Guicheux exemplifies the spirit of innovation in the medical field, particularly with his latest patents addressing critical health challenges. His work not only represents significant strides in diabetes and cardiology but also showcases the impact of collaboration and research in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.